JP Morgan Chase’s GreenLight Biosciences Holdings, PBC Common Stock GRNA Stock Holding History

JP Morgan Chase’s Portfolio GRNA Stock Details GRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-10,361	Closed	-$3.09K	–	7875
2023 Q2	$3.09K	Sell	10,361 -58,769	-85%	-$17.7K	﹤0.01%	6272
2023 Q1	$30K	Buy	69,130 +18,180	+36%	+$14K	﹤0.01%	5875
2022 Q4	$59K	Sell	50,950 -15,300	-23%	-$24.9K	﹤0.01%	5565
2022 Q3	$154K	Buy	66,250 +35,774	+117%	+$93.7K	﹤0.01%	5072
2022 Q2	$68K	Buy	30,476 +28,670	+1,587%	+$199K	﹤0.01%	5563
2022 Q1	$17K	Buy	+1,806	New	+$16.2K	﹤0.01%	6110
2021 Q4	–	Sell	-8,988	Closed	-$89K	–	7111
2021 Q3	$89K	Buy	+8,988	New	+$88.1K	﹤0.01%	5634

JP Morgan Chase's GRNA Position: Q3 2023 in Review

JP Morgan Chase sold out of GreenLight Biosciences Holdings, PBC Common Stock (GRNA) in Q3 2023, closing a stake of 10,361 shares — an estimated $3.09K sold.

JP Morgan Chase first reported a position in GRNA in Q3 2021 and held it in 7 quarters. The position peaked at $154K in Q3 2022. 0 funds tracked by Wall St. Rank hold GRNA as of Q3 2023.

JP Morgan Chase reported no remaining GreenLight Biosciences Holdings, PBC Common Stock position as of Q3 2023 after selling out during the quarter.
JP Morgan Chase sold 10,361 GreenLight Biosciences Holdings, PBC Common Stock shares in Q3 2023, an estimated $3.09K.
JP Morgan Chase first reported a position in GreenLight Biosciences Holdings, PBC Common Stock in Q3 2021 and held it in 7 quarters.
JP Morgan Chase's GreenLight Biosciences Holdings, PBC Common Stock position peaked at $154K in Q3 2022.
0 funds tracked by Wall St. Rank held GreenLight Biosciences Holdings, PBC Common Stock as of Q3 2023.

Based on JP Morgan Chase's 13F filing for Q3 2023, filed 14 Nov 2023.